HIV Treatment Advances: From Daily Pills to Six-Monthly Injections

HIV treatment has advanced more rapidly than almost any other area of medicine over the past four decades. What was once a near-certain death sentence is now a manageable chronic condition. The medications that made this possible — and the innovations continuing to improve them — are worth understanding, both for people with HIV and for anyone who follows this field.

Quick answer: Modern HIV treatment uses antiretroviral therapy (ART) — combinations of drugs that suppress HIV replication to undetectable levels. Single-pill, once-daily regimens are now standard. Long-acting injectable ART (cabotegravir + rilpivirine, every 2 months) became a major advance, allowing people to replace daily pills with bimonthly injections. Lenacapavir (Sunlenca) is a six-monthly injection approved for treatment-experienced patients with drug resistance. HIV cure research is ongoing but has not yet produced a scalable solution. Testing available in Los Angeles, New York City, Houston, Miami, and Washington DC.

The Current Standard: Single-Pill ART

Effective HIV treatment today typically involves a single combination pill taken once daily. Common regimens include bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy), dolutegravir/abacavir/lamivudine (Triumeq), and dolutegravir/lamivudine (Dovato). These integrate an integrase strand transfer inhibitor (INSTI) — the most effective drug class currently available — with backbone drugs that prevent viral replication through different mechanisms.

On an effective single-pill regimen, most people with HIV achieve an undetectable viral load within 3–6 months of starting treatment. Undetectable = Untransmittable (U=U): a person with HIV maintaining an undetectable viral load cannot sexually transmit the virus to a negative partner. Life expectancy for people starting HIV treatment early approaches that of HIV-negative individuals in high-income countries.

Long-Acting Injectable ART

The most significant advance in HIV treatment delivery in recent years is long-acting injectable antiretroviral therapy. Cabotegravir + rilpivirine (Cabenuva) was approved in the US in 2021 as the first complete long-acting injectable ART regimen. Administered as two intramuscular injections every 2 months by a healthcare provider, it replaces daily oral pills entirely for people who have already achieved viral suppression. Studies show it is as effective as daily oral ART for maintaining viral suppression, with high patient satisfaction. A monthly injection formulation is also available for patients who prefer monthly visits.

This innovation matters primarily for adherence: the barrier of remembering a daily pill is removed. For some people, this translates into better real-world adherence; for others, the requirement of bimonthly clinic visits may be less convenient than a daily pill. Both approaches are equally effective when used correctly.

Lenacapavir: A New Class for Resistant HIV

Lenacapavir (Sunlenca), approved in 2022, is the first in a new class of HIV drugs called capsid inhibitors. It is administered by subcutaneous injection twice yearly (every 6 months) and is currently approved for people with multi-drug resistant HIV who have failed other regimens. Its ultra-long-acting profile and novel mechanism make it particularly valuable for patients who have exhausted most other options. Lenacapavir is also under investigation as a twice-yearly injectable PrEP option — clinical trial results have shown high efficacy in prevention, which could transform the PrEP landscape if approved for that indication.

HIV Cure Research

A small number of people have been functionally cured of HIV through stem cell transplantation from donors with specific CCR5 genetic mutations (the “Berlin patient” and subsequent cases). These outcomes demonstrate that cure is biologically possible. However, stem cell transplantation is a high-risk procedure used only for patients requiring treatment for blood cancers, and is not a scalable cure strategy for the estimated 39 million people living with HIV globally.

Research directions include: broadly neutralising antibodies (bNAbs) that can suppress HIV without daily medication; gene editing approaches using CRISPR to excise HIV from latent reservoirs; and therapeutic vaccines designed to train the immune system to control HIV without ART. None of these approaches has yet produced a proven, scalable cure, but the scientific foundation is advancing.

Frequently Asked Questions

How do I know if my HIV treatment is working?

Viral load testing at 4–8 weeks after starting ART, and then every 3–6 months thereafter, confirms that the regimen is suppressing the virus. The goal is a viral load below the limit of detection (typically <20–50 copies/mL). CD4 count is monitored less frequently once viral suppression is established, as it recovers gradually over months to years.

Can I switch from daily pills to injectable ART?

Potentially, if you have achieved and maintained an undetectable viral load and do not have specific resistance mutations that would make cabotegravir or rilpivirine less effective. Discuss with your HIV clinician whether long-acting injectable ART is appropriate for your specific situation, including practical considerations around injection site visits.

Related: Understanding HIV · HIV Prevention and PrEP · HIV Facts and Myths · Get tested today →